Aquestive(US:AQST) Businesswire·2026-03-10 23:26Core Viewpoint - Rosen Law Firm has initiated a class action lawsuit against Aquestive Therapeutics, Inc. for allegedly misleading investors regarding its business operations and the status of its New Drug Application for Anaphylm [1] Group 1: Allegations - The lawsuit claims that Aquestive Therapeutics made false or misleading statements and failed to disclose the true state of its New Drug Application for Anaphylm [1] - It is alleged that the company concealed the significance of human factors related to the use of its sublingual film, including aspects such as packaging, use, administration, and labeling [1] - Investors reportedly suffered damages when the true details about the company's operations became public [1] Group 2: Class Action Participation - Shareholders who wish to serve as lead plaintiffs must file their motions with the court by May 4, 2026 [1] - A lead plaintiff represents other class members in directing the litigation, but participation is not required to be eligible for recovery [1] - All representation in this case is on a contingency fee basis, meaning shareholders incur no fees or expenses [1] Group 3: About Rosen Law Firm - Rosen Law Firm is recognized for its focus on shareholder rights litigation and has recovered over $1 billion for shareholders since its inception [1] - The firm emphasizes its commitment to improving corporate governance and holding executives accountable for wrongdoing [1]